Vincristine sulfate liposomal injection for acute lymphoblastic leukemia

Abstract

Vincristine (VCR) is one of the most extensively used cytotoxic compounds in hemato-oncology. VCR is particularly important for the treatment of acute lymphoblastic leukemia (ALL), a disease that accounts for approximately one-third of all childhood cancer diagnoses. VCR's full therapeutic potential has been limited by dose-limiting neurotoxicity, classically resulting in autonomic and peripheral sensory-motor neuropathy. In the last decade, however, the discovery that liposomal encapsulation of chemotherapeutics can modulate the pharmacokinetic characteristics of a compound has stimulated much interest in liposomal VCR (vincristine sulfate liposomal injection [VSLI]) formulations for the treatment of ALL and other hematological malignancies. Promising data from recent clinical trials investigating VSLI in adults with ALL resulted in US Food and Drug Administration approval for use in patients with Philadelphia chromosome (t[9;22]/BCR-ABL1) (Ph)-negative (Ph-) disease. Additional clinical trials of VSLI in adults and children with both Ph-positive (Ph+) and Ph- ALL are ongoing. Here we review the preclinical and clinical experience to date with VSLI for ALL.J Paediatr Child Health. 2010 Nov;46(11):698-9. (PMID: 21077980); J Cell Sci. 1992 Jul;102 ( Pt 3):401-16. (PMID: 1506423); Cancer. 2009 Dec 1;115(23):5490-8. (PMID: 19708032); Cancer Chemother Pharmacol. 2013 Mar;71(3):555-64. (PMID: 23212117); Cancer Chemother Pharmacol. 1993;33(1):17-24. (PMID: 8269584); Methods Enzymol. 2005;391:40-57. (PMID: 15721373); Anal Biochem. 1995 Dec 10;232(2):149-57. (PMID: 8747469); Cancer Res. 1985 Jun;45(6):2741-7. (PMID: 3986806); J Paediatr Child Health. 2011 Dec;47(12):875-82. (PMID: 21658147); Braz J Med Biol Res. 2009 Jun;42(6):567-73. (PMID: 19448908); Acta Pharmacol Sin. 2012 Jun;33(6):852-8. (PMID: 22669119); Pharm Res. 2001 Sep;18(9):1331-5. (PMID: 11683249); Pediatr Blood Cancer. 2009 Dec 15;53(7):1180-7. (PMID: 19588521); Cancer. 2003 Dec 15;98(12):2643-50. (PMID: 14669284); J Clin Oncol. 2013 Feb 20;31(6):676-83. (PMID: 23169518); Biochim Biophys Acta. 2001 Jul 2;1513(1):25-37. (PMID: 11427191); Cancer Res. 1994 Jun 1;54(11):2830-3. (PMID: 8187061); J Pediatr. 2007 Nov;151(5):548-50. (PMID: 17961705); ISRN Pharm. 2012;2012:738432. (PMID: 22474607); Proc Natl Acad Sci U S A. 1991 Dec 15;88(24):11460-4. (PMID: 1763060); Nature. 1983 Nov 17-23;306(5940):277-80. (PMID: 6580527); Br J Cancer. 1995 Oct;72(4):896-904. (PMID: 7547237); J Clin Invest. 2002 Jul;110(1):91-9. (PMID: 12093892); J Clin Pharmacol. 2006 Jul;46(7):727-37. (PMID: 16809798); J Pharmacol Exp Ther. 2001 Sep;298(3):1206-12. (PMID: 11504822); Lancet. 2008 Mar 22;371(9617):1030-43. (PMID: 18358930); Eur Biophys J. 2009 Dec;39(1):103-10. (PMID: 19132364); Acta Oncol. 2002;41(2):197-9. (PMID: 12102167); Cancer Res. 1991 Apr 15;51(8):2212-22. (PMID: 2009540); Lancet. 2013 Jun 1;381(9881):1943-55. (PMID: 23523389); J Clin Pharmacol. 2011 Aug;51(8):1205-12. (PMID: 20978276); Ann N Y Acad Sci. 1958 Dec 5;76(3):882-94. (PMID: 13627916); Cancer. 2006 Jan 1;106(1):120-7. (PMID: 16331634); Semin Diagn Pathol. 2013 Feb;30(1):29-44. (PMID: 23327728); Curr Oncol Rep. 2008 Sep;10(5):379-87. (PMID: 18706265); Crit Rev Oncol Hematol. 1999 Feb;29(3):267-87. (PMID: 10226730); J Pediatr Hematol Oncol. 2009 Nov;31(11):816-9. (PMID: 19801949); Cancer Res. 1963 Sep;23:1390-427. (PMID: 14070392); Br J Haematol. 1997 Mar;96(3):601-10. (PMID: 9054669); J Clin Oncol. 2009 Nov 1;27(31):5175-81. (PMID: 19805687); Biochim Biophys Acta. 1993 Nov 7;1152(2):253-8. (PMID: 8218326). Linking ISSN: 11769114. Subset: MEDLINE; Date of Electronic Publication: 2013 Nov 06. ; Original Imprints: Publication: Auckland : DOVE Medical Press <br />